AU2003286931A8 - Methods and compositions using thalidomide for the treatment and management of cancers and other diseases - Google Patents

Methods and compositions using thalidomide for the treatment and management of cancers and other diseases

Info

Publication number
AU2003286931A8
AU2003286931A8 AU2003286931A AU2003286931A AU2003286931A8 AU 2003286931 A8 AU2003286931 A8 AU 2003286931A8 AU 2003286931 A AU2003286931 A AU 2003286931A AU 2003286931 A AU2003286931 A AU 2003286931A AU 2003286931 A8 AU2003286931 A8 AU 2003286931A8
Authority
AU
Australia
Prior art keywords
thalidomide
cancers
diseases
compositions
management
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003286931A
Other versions
AU2003286931A1 (en
Inventor
Jerome B Zeldis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AU2003286931A1 publication Critical patent/AU2003286931A1/en
Publication of AU2003286931A8 publication Critical patent/AU2003286931A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
AU2003286931A 2003-11-06 2003-11-06 Methods and compositions using thalidomide for the treatment and management of cancers and other diseases Abandoned AU2003286931A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/035546 WO2005046686A1 (en) 2003-11-06 2003-11-06 Methods and compositions using thalidomide for the treatment and management of cancers and other diseases

Publications (2)

Publication Number Publication Date
AU2003286931A1 AU2003286931A1 (en) 2004-06-06
AU2003286931A8 true AU2003286931A8 (en) 2005-06-06

Family

ID=34589309

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003286931A Abandoned AU2003286931A1 (en) 2003-11-06 2003-11-06 Methods and compositions using thalidomide for the treatment and management of cancers and other diseases

Country Status (2)

Country Link
AU (1) AU2003286931A1 (en)
WO (1) WO2005046686A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0522080D0 (en) * 2005-10-28 2005-12-07 Cancer Rec Tech Ltd Tnf alpha-ngf molecular switch for determining cell fate
EP2870480A4 (en) * 2012-07-05 2016-03-23 Caldera Health Ltd Methods for determining personalized treatment compositions for prostate cancer and breast cancer
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5731325A (en) * 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
CA2319872C (en) * 2000-02-02 2012-06-19 Chun-Ying Huang Pharmaceutical composition for the treatment of hepatocellular carcinoma
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer

Also Published As

Publication number Publication date
WO2005046686A1 (en) 2005-05-26
AU2003286931A1 (en) 2004-06-06

Similar Documents

Publication Publication Date Title
IL175427A0 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
EP1635826A4 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
IL172194A0 (en) Methods and compositions for treating amyloid-related diseases
EP1567158A4 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
EP1567157A4 (en) Methods of using and compositions comprising immunomudulatory compounds for the treatment and management of myeloproliferative diseases
EP1663259A4 (en) Compositions and methods for treatment of cancer
IL184047A0 (en) Methods and compositions for treating amyloid-related diseases
IL175529A0 (en) Methods and compositions for the treatment of metabolic disorders
IL175425A0 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
EP1572116A4 (en) Compositions and methods for the treatment of immune related diseases
IL174627A0 (en) Compositions and methods for treatment of burns
EP1613266A4 (en) Methods of treating pain and compositions for use therefor
AU2003286741A8 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
EP1680145A4 (en) Methods and compositions for the treatment of neurological disease
GB0303609D0 (en) Novel therapeutic method and compositions
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
IL176453A0 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
AU2003237792A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1576109A4 (en) Methods and compositions for categorizing patients
HK1104800A1 (en) Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
GB0324523D0 (en) Compositions and methods of treatment
EP1680132A4 (en) Methods of using and compositions comprising thalidomide for treatment, modification and management of fibromyalgia
IL166062A0 (en) Compositions and methods for therapeutic treatment
AU2003286931A8 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
GB0327050D0 (en) Therapeutic methods compositions and uses

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 19, NO 28, PAGE(S) 1849 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME CELGENE CORPORATION, APPLICATION NO. 2003286931, UNDER INID (43) CORRECT THE DATE TO READ 06.06.2005

MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase